Regulatory Strategy and Commercialization Planning

The contract seeks to develop a comprehensive regulatory roadmap aimed at securing FDA approval and establishing a commercialization strategy for technologies targeting both military and civilian markets. This includes strategic engagement with FDA regulatory pathways as well as Department of Defense acquisition channels to facilitate timely market entry and adoption. The work will require deep expertise in regulatory science, medical device or pharmaceutical development frameworks, and defense procurement systems to align product development with dual-use operational needs and compliance requirements. The subcontract will involve detailed planning, stakeholder coordination, and documentation to navigate the complex interplay between clinical validation, safety standards, and military operational requirements. The opportunity is posted under NAICS code 541618 for other scientific and technical consulting services and is issued by the Defense Advanced Research Projects Agency under the Department of Defense. While no set-aside designation is specified, responses are due by May 19, 2026, and the performance location is not defined, indicating flexibility in execution. The focus is on delivering a structured, actionable plan that bridges regulatory science with defense and public health commercialization pathways, ensuring the technology can be rapidly integrated into both battlefield and civilian healthcare environments upon approval.